Structure Therapeutics (NASDAQ:GPCR) Reaches New 52-Week Low - Here's Why

Key Points

• Structure Therapeutics shares hit a new 52-week low, trading as low as $20.40 and down 0.4%, well below their 50-day and 200-day moving averages.
• Despite the decline, analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and a $110.91 price target; however, Wall Street Zen downgraded the stock to “Strong Sell.”
• The company missed its latest earnings expectations, reporting a quarterly loss of $0.49 per share versus the estimated $0.39 loss. Structure is developing GSBR-1290, an oral GLP-1 drug candidate for obesity and type 2 diabetes.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report)'s share price reached a new 52-week low during trading on Tuesday. The stock traded as low as $20.40 and last traded at $20.3950, with a volume of 358,869 shares changing hands. The stock had previously closed at $20.47.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Citizens Jmp reissued a "market outperform" rating and issued a $110.00 price target on shares of Structure Therapeutics in a report on Wednesday, September 9th. Citigroup restated a "market outperform" rating on shares of Structure Therapeutics in a report on Friday, August 7th. Wall Street Zen cut Structure Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, October 3rd. HC Wainwright reiterated a "buy" rating on shares of Structure Therapeutics in a report on Wednesday, September 9th. Finally, Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a report on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Structure Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $110.91.

Structure Therapeutics Trading Down 0.4%

The stock has a market cap of $1.42 billion, a P/E ratio of -20.38 and a beta of -1.12. The firm has a 50-day simple moving average of $32.86 and a two-hundred day simple moving average of $49.16.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.10). Sell-side analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.87 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Assetmark Inc. boosted its stake in shares of Structure Therapeutics by 21.4% in the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company's stock valued at $123,000 after purchasing an additional 449 shares during the last quarter. Sterling Capital Management LLC bought a new position in Structure Therapeutics during the first quarter worth $28,000. IFP Advisors Inc bought a new position in Structure Therapeutics during the second quarter worth $46,000. Parallel Advisors LLC lifted its holdings in Structure Therapeutics by 12.7% in the third quarter. Parallel Advisors LLC now owns 8,286 shares of the company's stock valued at $259,000 after buying an additional 934 shares during the period. Finally, Cetera Investment Advisers lifted its holdings in Structure Therapeutics by 17.0% in the first quarter. Cetera Investment Advisers now owns 7,720 shares of the company's stock valued at $372,000 after buying an additional 1,124 shares during the period. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics NASDAQ: GPCR is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic diseases. The company uses structure-based drug discovery and focuses on G protein-coupled receptors (GPCRs), a broad class of drug targets involved in metabolic and cardiovascular processes.

Its lead product candidate is GSBR-1290, an investigational oral GLP-1 receptor agonist being developed for obesity and type 2 diabetes. Structure Therapeutics is also advancing additional discovery and preclinical programs intended to address metabolic and related chronic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.